By Fineline Cube 
ZEISS Medical Technology announced that the National Medical Products Administration (NMPA) has approved the ARTEVO 750 and ARTEVO 850 ophthalmic microscopes for use in China. The digital microscopes provide high‑quality optical and digital visualization for both anterior and posterior segment surgeries, featuring hardware and software upgrades that enhance surgical precision and safety.
Regulatory Milestone & Product Profile
| Item | Detail |
|---|---|
| Company | ZEISS Medical Technology |
| Products | ARTEVO 750 and ARTEVO 850 ophthalmic microscopes |
| Approval | NMPA marketing authorization |
| Indications | Anterior and posterior segment ophthalmic surgeries |
| Key Features | Enhanced resolution, RGB illumination, digital visualization |
| Strategic Value | Full compatibility with latest generation ZEISS cataract workflow |
| Innovation | Hardware and software upgrades for more precise operations |
Market Impact & Commercial Outlook
- China Ophthalmology Device Market: Valued at ¥8 billion : (~US$1.1 billion) in 2025, growing at 12% CAGR driven by rising cataract surgery volumes and premium IOL adoption
- Microscope Segment: Digital ophthalmic microscopes represent ¥1.5 billion : sub‑segment; ARTEVO’s approval positions ZEISS against Leica Microsystems and Alcon
- Surgical Precision: Enhanced resolution and RGB illumination improve visualization of delicate ocular structures, potentially reducing surgical complications
- Workflow Integration: Compatibility with ZEISS’s cataract workflow creates a comprehensive ecosystem, encouraging hospital system purchases
- Revenue Potential: Analysts project ¥300–500 million : (US$42–70 million) peak annual sales for ARTEVO 750/850 in China by 2028, assuming 20% share of premium microscope market
- Strategic Value: Strengthens ZEISS’s presence in China’s high‑growth ophthalmic surgery market; complements existing IOL and diagnostic equipment portfolio
- Next Steps: Commercial launch expected Q2 2026; training programs for surgeons at major eye hospitals to commence immediately
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch timelines, market penetration, and revenue projections for ARTEVO 750/850. Actual results may differ due to competitive dynamics, hospital adoption rates, and reimbursement negotiations.-Fineline Info & Tech